🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise around the world, with data suggesting more than 82 million new cases each year. Notably increased rates are reported in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This approval signifies a significant shift in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Results and Global Access

According to findings detailed in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which involves an injection and a pill. The trial enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians treating patients have shared optimism. The availability of a easy-to-administer therapy such as this is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.